Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
Status:
Completed
Trial end date:
2020-03-16
Target enrollment:
Participant gender:
Summary
The standard of care for muscle-invasive bladder cancer (MIBC) is radical cystectomy, which
is rarely curative. Platinum-based neoadjuvant chemotherapy is associated with an improvement
in Overall Survival (OS), but only a few patients can benefit from this approach. Therefore,
new neoadjuvant treatments are required for muscle- invasive bladder cancer. In this study it
will be explored the activity of durvalumab plus olaparib in advanced Transitional Cell
Carcinoma of the Bladder and therefore may have beneficial outcomes in the neoadjuvant
setting. Adverse events associated with durvalumab and olaparib is one of the potential risks
in this study. Participation in this trial, in which 6-8 weeks of preoperative treatment will
be administered, is not expected to result in delays of surgery for participants. It is not
foreseen that treatment with durvalumab and olaparib has a relevant impact on operability or
increases the risks associated with surgery